What is your presentation about?
My talk is about a physiological feedback system, termed the liver-alpha cell axis, in which glucagon contributes to key metabolic traits such as amino acid and lipid metabolism. I am excited to share our preclinical and clinical data on how the liver-alpha cell axis is essential for our metabolic health and how manipulating it may have therapeutic aspects.
What makes this topic important in 2022?
Inter-organ crosstalk is essential to understand the complexity of diabetes. The liver-alpha cell axis is a conceptual rethinking of glucagon biology offering an explanation to why patients with type 2 diabetes have hyperglucagonemia and how fatty liver disrupts the liver-alpha cell axis.
How did you become involved with this area of diabetes research or care?
Eleven years ago I became interested in glucagon biology after a seminar with my now mentor Prof. Jens Juul Holst in medical school and since that time have not been thinking about much else.
What are you most looking forward to at the 82nd Scientific Sessions?
To meet the community, share our data and importantly to get feedback and criticism on our science. Finally I am quite excited to learn the latest on the dual agonist with GLP-1-GIP and GLP-1-Glucagon.